Results from a population-based cohort study
[DOI] [PMC free article] [PubMed] [Google Scholar] (64).Tang X
Still University, Mesa, AZ, USA Irina Filip Institute of Public Health, Charit Universittsmedizin Berlin (Charit Medical University Berlin), Berlin, Germany Florian Fischer School of Social Sciences, Stretton Health Equity, Adelaide, SA, Australia Joanne Flavel Center for Research in Indigenous Health, Maya Health Alliance, Tecpn, Guatemala David Flood Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA David Flood Department of Child Dental Health, Ile-Ife, Nigeria Morenike Oluwatoyin Folayan Department of Clinical Science, Nigerian Institute of Medical Research, Yaba, Nigeria Morenike Oluwatoyin Folayan Department of Neurology, University of Lisbon, Lisbon, Portugal Ana Catarina Fonseca Neurology Department, Hospital de Santa Maria, Lisbon, Portugal Ana Catarina Fonseca Neurology, Public Health, Disability Unit, Beijing Neurosurgical Institute, Milano, Italy Arianna Fornari Department of Pharmacology, Iranshahr University of Medical Sciences, Iranshahr, Iran Behzad Foroutan Child Survival Unit, Centre for African Newborn Health and Nutrition, Ibadan, Nigeria Kayode Raphael Fowobaje Department of Community Medicine, Information and Health Decision Sciences, University of Porto, Porto, Portugal Alberto Freitas Center for Health Technology and Services Research (CINTESIS), Porto, Portugal Alberto Freitas Associated Laboratory for Green Chemistry (LAQV), University of Porto, Porto, Portugal Marisa Freitas, Nelson G
Ginsenoside Rh4 inhibits inflammation-related hepatocellular carcinoma progression by targeting HDAC4/IL-6/STAT3 signaling
The anticancer effects of ginsenosides and oxymatrine have been mentioned above [242]
